Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) provide dramatic response to patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). However, the use of neoadjuvant therapy with EGFR-TKIs in EGFR-mutant NSCLC remains controversial, especially in pulmonar...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiguang, Zheng, Yating, Mai, Shijie, Tong, Yu, Yang, Lili, Huang, Mengli, Cai, Ruijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733669/
https://www.ncbi.nlm.nih.gov/pubmed/36505870
http://dx.doi.org/10.3389/fonc.2022.1033322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733669/
https://www.ncbi.nlm.nih.gov/pubmed/36505870
http://dx.doi.org/10.3389/fonc.2022.1033322

Ejemplares similares